SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.
Key Points:
- SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.
- To access a live webcast of the presentation, please visit the Events page in the Investors section of the Company’s website at www.turnstonebio.com .
- Members of Turnstone’s senior management will also be available for one-on-one meetings during the conference.
- Interested investors should contact their Bank of America Securities representative for further information.
University,
CFO,
LLP,
Champaign–Urbana metropolitan area,
Certification,
Arrowhead Pharmaceuticals,
TILS,
PwC,
Biotechnology Innovation Organization,
BIO,
Selection,
TIL,
SVP,
Senior,
Patient,
OncoMed,
Therapy,
Biotechnology,
SAN,
Pharmaceutical industry SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
Key Points:
- SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
- The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
- “I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
- “Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.
Administration,
Head,
TIL,
Colorectal cancer,
Immunotherapy,
HNSCC,
Takeda Oncology,
Selection,
Patient,
G&A,
Melanoma,
TILS,
Investment,
CRC,
Breast cancer,
SITC,
Research and development,
Research institute,
Turnstone,
Uveal melanoma SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
Key Points:
- “2023 marked a transformative year for Turnstone Biologics in which we transitioned into a publicly traded company and continued to advance our pipeline through clinical development.
- Recently, Turnstone expanded their trials to evaluate additional solid tumor types in addition to the existing indications of breast cancer and uveal melanoma.
- Preclinical Data Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Support Ongoing Clinical and Preclinical Efforts.
- Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.
Retrieved on:
Wednesday, February 21, 2024
SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences:
Key Points:
- SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences:
Retrieved on:
Tuesday, February 20, 2024
Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer, commented, “This is a moment of profound sadness for those of us who had the privilege of knowing Joseph.
Key Points:
- Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer, commented, “This is a moment of profound sadness for those of us who had the privilege of knowing Joseph.
- Joseph will be deeply remembered for his remarkable passion, intellectual curiosity, exemplary character and integrity, and unwavering dedication to improving the lives of people living with cancer.
- On behalf of the entire Turnstone team, I would like to extend our sincerest sympathies to Joseph’s family and loved ones.”
Dr. Farah continued, “With Joseph’s passing, Turnstone has suffered a great loss.
- However, the Company is confident that the rest of the management team will continue to lead Turnstone forward and capitalize on the legal and compliance principles that Joseph established at Turnstone."
Retrieved on:
Monday, November 27, 2023
SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer, will participate in the Piper Sandler 35th Annual Healthcare Conference taking place November 28 – 30, 2023 in New York, NY.
Key Points:
- SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer, will participate in the Piper Sandler 35th Annual Healthcare Conference taking place November 28 – 30, 2023 in New York, NY.
- Details of participation are as follows:
A live webcast of the fireside chat may be accessed on the Events page of Turnstone’s Investor Relations website at https://ir.turnstonebio.com , where a replay will also be available for a limited period.
- Institutional investors interested in meeting with members of Turnstone’s senior management team during the conference may contact their Piper Sandler representatives for further information.
Retrieved on:
Friday, November 10, 2023
Uveal melanoma,
Selection,
Colorectal cancer,
Investment,
Breast cancer,
Administration,
Patient,
Piper Sandler Companies,
Melanoma,
Immunotherapy,
Takeda Oncology,
Conference,
IPO,
SITC,
R,
Research and development,
Coronavirus Scientific Advisory Board,
Physician,
TIL,
Research institute,
Pharmaceutical industry,
Turnstone SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.
Key Points:
- In October 2023, Turnstone appointed Jeffrey S. Weber, M.D., Ph.D., to its Scientific Advisory Board.
- In July 2023, Turnstone priced its initial public offering (IPO) at $12.00 per share.
- Cash, Cash Equivalents and Short-Term Investments: As of September 30, 2023, cash, cash equivalents and short-term investments were $109.1 million.
- Net Loss: Net loss for the three months ended September 30, 2023, was $17.3 million, compared to net loss of $16.2 million for the third quarter of 2022.
Neoplasm,
Colon,
Breast,
Stomach,
Somatic mutation,
RNA,
Society for Immunotherapy of Cancer,
CRISPR,
TIL,
SITC,
Immunotherapy,
Selection,
Annual general meeting,
Gene,
Melanoma,
Society,
Liquid biopsy,
Patient,
SAN,
DNA,
Pharmaceutical industry,
Medical imaging,
Turnstone SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting four posters highlighting preclinical data from its pipeline of programs, including the lead clinical candidate, TIDAL-01, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting being held November 1-5, 2023 in San Diego, California.
Key Points:
- We are pleased to share the promising results presented at SITC that further highlight our differentiated approach.
- Identifying tumor-specific neoantigens arising from somatic mutations is one of the differentiating features of Turnstone’s Selected TIL process for TIDAL-01.
- Distinct from, yet complementary to TIDAL-01, Turnstone is developing a preclinical program associated with a next-generation direct selection process.
- Turnstone scientists are presenting preclinical data highlighting that directly selected tumor-reactive TIL can be genetically engineered using CRISPR-Cas and demonstrate that knocking out genes of interest can potentially enhance directly selected TIL quality and function.
American Society of Clinical Oncology,
TILS,
Principal,
New York University Grossman School of Medicine,
NCI,
Rockefeller University,
Clinical Oncology,
Research,
TIL,
Centers of Biomedical Research Excellence,
NYU,
Selection,
Melanoma,
National Cancer Institute,
PCC,
Patient,
Veteran,
SAB,
SPORE,
Skin cancer,
SAN,
United States Air Force Scientific Advisory Board,
Pharmaceutical industry,
Medical imaging,
Turnstone,
Medicine “We are very pleased to welcome Dr. Weber to the Turnstone Scientific Advisory Board,” said Stewart Abbot, Ph.D., Turnstone.
Key Points:
- “We are very pleased to welcome Dr. Weber to the Turnstone Scientific Advisory Board,” said Stewart Abbot, Ph.D., Turnstone.
- Weber’s work has led to groundbreaking achievements in cancer immunotherapy, and he brings unique expertise and perspective to our SAB.
- “Turnstone is advancing a differentiated approach to TIL therapy and I am delighted to join the esteemed members of Turnstone’s SAB,” said Dr. Weber.
- I look forward to partnering with Turnstone to deliver the next-generation of TIL therapies to underserved patient populations.”
Retrieved on:
Thursday, September 28, 2023
SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced four posters reporting preclinical data for Turnstone’s Selected TIL therapies will be presented at the 38 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Key Points:
- SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced four posters reporting preclinical data for Turnstone’s Selected TIL therapies will be presented at the 38 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
- The SITC 38th Annual Meeting will be held from November 1-5, 2023, in San Diego, California.
- The details of the posters are as follows:
